Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: TET2 suppresses nasopharyngeal carcinoma progression by inhibiting glycolysis metabolism

Fig. 6

TET2 inhibiting NPC progress in vivo depends on PKM. a The tumor volume of nude mice with established subcutaneous TET2-WT (control) and TET2-knockout (TET2-cas9) xenografts was recorded. b The survival curve of nude mice with established subcutaneous TET2-WT (control) and TET2-knockout (TET2-cas9) xenografts was calculated. c Nude mice with established subcutaneous TET2-WT xenografts were treated with the PKM inhibitor (PKM-In), shikonin (5 mg/kg) or PBS for every 2 days. The animals were maintained for post-treatment observation. The tumor volume of nude mice was recorded. d The survival curve of the indicated nude mice was calculated. e Nude mice with established subcutaneous with TET2-knockout (TET2-cas9) xenografts were treated with the PKM inhibitor (PKM-In), shikonin (5 mg/kg) or PBS for every 2 days. The animals were maintained for post-treatment observation. The tumor volume of nude mice was recorded. d The survival curve of the indicated nude mice was calculated. Data are represented as mean ± SD (n = 3; *represents P < 0.05)

Back to article page
\